JP2015512255A - ざ瘡の高速診断および個人化された治療 - Google Patents

ざ瘡の高速診断および個人化された治療 Download PDF

Info

Publication number
JP2015512255A
JP2015512255A JP2015501822A JP2015501822A JP2015512255A JP 2015512255 A JP2015512255 A JP 2015512255A JP 2015501822 A JP2015501822 A JP 2015501822A JP 2015501822 A JP2015501822 A JP 2015501822A JP 2015512255 A JP2015512255 A JP 2015512255A
Authority
JP
Japan
Prior art keywords
seq
acne
strain
strains
phage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015501822A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512255A5 (https=
Inventor
フイイン リー，
フイイン リー，
秀太 冨田
秀太 冨田
ロバート エル． モドリン，
ロバート エル． モドリン，
ジェフリー エフ． ミラー，
ジェフリー エフ． ミラー，
ソレル ティー． フィッツ−ギボン，
ソレル ティー． フィッツ−ギボン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Los Angeles UCLA
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2015512255A publication Critical patent/JP2015512255A/ja
Publication of JP2015512255A5 publication Critical patent/JP2015512255A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2015501822A 2012-03-17 2013-03-15 ざ瘡の高速診断および個人化された治療 Withdrawn JP2015512255A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612290P 2012-03-17 2012-03-17
US61/612,290 2012-03-17
PCT/US2013/032551 WO2013142378A1 (en) 2012-03-17 2013-03-15 Fast diagnosis and personalized treatments for acne

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019002573A Division JP2019050833A (ja) 2012-03-17 2019-01-10 ざ瘡の高速診断および個人化された治療

Publications (2)

Publication Number Publication Date
JP2015512255A true JP2015512255A (ja) 2015-04-27
JP2015512255A5 JP2015512255A5 (https=) 2016-05-12

Family

ID=49223275

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015501822A Withdrawn JP2015512255A (ja) 2012-03-17 2013-03-15 ざ瘡の高速診断および個人化された治療
JP2019002573A Pending JP2019050833A (ja) 2012-03-17 2019-01-10 ざ瘡の高速診断および個人化された治療
JP2020188630A Pending JP2021013395A (ja) 2012-03-17 2020-11-12 ざ瘡の高速診断および個人化された治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019002573A Pending JP2019050833A (ja) 2012-03-17 2019-01-10 ざ瘡の高速診断および個人化された治療
JP2020188630A Pending JP2021013395A (ja) 2012-03-17 2020-11-12 ざ瘡の高速診断および個人化された治療

Country Status (9)

Country Link
US (5) US20150086581A1 (https=)
EP (3) EP2825676B1 (https=)
JP (3) JP2015512255A (https=)
CN (2) CN104364394B (https=)
AU (3) AU2013235340B2 (https=)
BR (1) BR112014023005A2 (https=)
CA (1) CA2867621A1 (https=)
SG (1) SG11201405783VA (https=)
WO (1) WO2013142378A1 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017014256A1 (ja) * 2015-07-21 2017-01-26 ＴＡＫ－Ｃｉｒｃｕｌａｔｏｒ株式会社 身体状態の評価方法、情報の提示方法、および身体状態を改善又は予防する物質のスクリーニング方法
JP2017086072A (ja) * 2015-11-04 2017-05-25 学校法人慶應義塾 対象物の使用者を判定する方法
JP6231252B1 (ja) * 2016-07-08 2017-11-15 花王株式会社 核酸試料の調製方法
US9889165B2 (en) 2016-04-21 2018-02-13 Naked Biome, Inc. Compositions and methods for treatment of skin disorders
WO2018084112A1 (ja) 2016-11-01 2018-05-11 株式会社桃谷順天館 アクネ菌株選択的抗菌剤
JP2019509263A (ja) * 2016-02-05 2019-04-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 皮膚の健康増進用組成物及び健康増進方法
JP2020517735A (ja) * 2017-04-21 2020-06-18 ピー・エイチ・アイ・セラピューティクス・インコーポレイテッド ざ瘡を治療するためのプロピオニバクテリウムアクネス（Ｐｒｏｐｉｏｎｉｂａｃｔｅｒｉｕｍ ａｃｎｅｓ）バクテリオファージを含む組成物
JP2022539826A (ja) * 2019-07-12 2022-09-13 ビオメリュー 細菌発生の疫学的識別および監視のための方法

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11191665B2 (en) 2011-02-04 2021-12-07 Joseph E. Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US10085938B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for preventing sore throat in humans
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10111913B2 (en) 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10583033B2 (en) 2011-02-04 2020-03-10 Katherine Rose Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US10010568B2 (en) 2011-02-04 2018-07-03 Katherine Rose Kovarik Method and system for reducing the likelihood of a spirochetes infection in a human being
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
EP2825676B1 (en) 2012-03-17 2017-12-20 The Regents of The University of California Fast diagnosis and personalized treatments for acne
US11072832B2 (en) 2013-06-18 2021-07-27 Prodermiq, Inc. Customized skin care products and personal care products based on the analysis of skin flora
JP6637885B2 (ja) 2013-07-21 2020-01-29 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオームの特性解明、モニタリング、および処置のための方法およびシステム
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12318377B2 (en) 2013-12-20 2025-06-03 Seed Health, Inc. Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
EP4299122A3 (en) * 2014-05-07 2024-03-27 The Regents of The University of California Compositions and methods for treating skin and mucous membrane diseases
SI3158054T1 (sl) 2014-06-17 2025-06-30 Crown Laboratories, Inc. Genetsko modificirane bakterije in postopki za genetsko modifikacijo bakterij
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
SG11201701245QA (en) 2014-08-27 2017-03-30 Caribou Biosciences Inc Methods for increasing cas9-mediated engineering efficiency
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
WO2016065075A1 (en) 2014-10-21 2016-04-28 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
AU2016250100A1 (en) * 2015-04-13 2017-11-09 Psomagen, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
EP3285872A4 (en) * 2015-04-20 2019-02-20 S-Biomedic NV METHOD AND COMPOSITIONS FOR CHANGING THE COMPOSITION OF SKIN MICROBIOMA WITH COMPLEX MIXTURES OF BACTERIAL BARS
CN108271392B (zh) * 2015-08-06 2023-01-10 阿瑞斯遗传股份有限公司 在微生物中利用基因组中结构变化对抗微生物药物的基因抗性预测
US11773455B2 (en) 2015-09-09 2023-10-03 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics infectious disease and other health conditions associated with antibiotic usage
EP3346910A4 (en) * 2015-09-09 2019-05-15 Ubiome Inc. METHOD AND COMPOSITIONS FOR MICROBIOMA DIAGNOSIS AND THERAPEUTIC AGAINST ECCEM
WO2017044885A1 (en) * 2015-09-09 2017-03-16 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with cerebro-craniofacial health
US10679725B2 (en) 2015-09-17 2020-06-09 Prodermiq, Inc. Predicting skin age based on the analysis of skin flora and lifestyle data
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
GB2544481B (en) * 2015-11-16 2019-12-11 Century International Enterprises Ltd A wearable article and a method for producing a wearable article
US10568916B2 (en) 2015-11-30 2020-02-25 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US10086024B2 (en) 2015-11-30 2018-10-02 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US10933128B2 (en) 2015-11-30 2021-03-02 Joseph E. Kovarik Method and system for protecting honey bees from pesticides
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
US10675347B2 (en) 2015-11-30 2020-06-09 Joseph E. Kovarik Method and system for protecting honey bees from fipronil pesticides
US11529412B2 (en) 2015-11-30 2022-12-20 Seed Health, Inc. Method and system for protecting honey bees from pesticides
WO2017147507A1 (en) 2016-02-24 2017-08-31 Xycrobe Therapeutics, Inc. Skin probiotic formulation
WO2017185018A1 (en) * 2016-04-21 2017-10-26 Naked Biome, Inc. Synthetic bacteria and methods of use
CA3022294A1 (en) * 2016-04-25 2017-11-02 uBiome, Inc. Method and system for characterizing skin-related conditions
EP3243907A1 (en) * 2016-05-13 2017-11-15 Curetis GmbH Stable pan-genomes and their use
CN109689861A (zh) * 2016-05-15 2019-04-26 加州大学评议会 用于治疗痤疮的组合物和方法
CN106167820A (zh) * 2016-05-19 2016-11-30 胤安国际（辽宁）基因科技股份有限公司 鉴定或辅助鉴定痤疮丙酸杆菌的专用引物及其应用
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
US11541081B2 (en) 2016-10-19 2023-01-03 S-Biomedic Nv Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains
EP3538119A4 (en) * 2016-11-08 2020-07-01 The Regents of The University of California COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES AND MAINTAINING HEALTHY SKIN
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US11915795B2 (en) * 2016-12-23 2024-02-27 The Regents Of The University Of California Method and device for digital high resolution melt
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
CA3055930A1 (en) 2017-03-10 2018-09-13 Prodermiq, Inc. Customized skin care products and personal care products based on the analysis of skin flora
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
WO2019079612A1 (en) * 2017-10-20 2019-04-25 Naked Biome, Inc. SYSTEMS AND METHODS OF BACTERIAL DETECTION AND TREATMENT
US20210177920A1 (en) * 2017-12-05 2021-06-17 Biomx Ltd. Bacteriophage treatment for acne and biofilms
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020055547A2 (en) 2018-08-18 2020-03-19 Seed Health, Inc. Methods and compositions for honey bee health
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US20220002782A1 (en) * 2018-11-01 2022-01-06 Kao Corporation Method for preparing nucleic acid derived from skin cell of subject
CA3118524A1 (en) * 2018-11-16 2020-05-22 S-biomedic N.v. Compositions for treating oxidative stress-associated skin diseases and skin ageing and diagnosis of oxidative stress-associated skin diseases
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
KR102746770B1 (ko) * 2019-07-10 2024-12-30 루오웨이 지앙 피부 분석을 위한 이미지들을 프로세싱하고 피부 분석을 시각화하기 위한 시스템들 및 방법들
EP3999624B1 (en) 2019-07-16 2026-03-25 Meliolabs Inc. Methods and devices for single-cell based digital high resolution melt
EP4003381A4 (en) * 2019-07-22 2024-02-28 The Regents of the University of California COMPOSITIONS AND METHODS FOR TREATING SKIN INFECTIONS AND OTHER DISEASES
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
US12516309B2 (en) 2019-10-31 2026-01-06 University Of Maryland, College Park Method of treating infections by bacteriolytic enzymes and manufacture thereof
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
US12102710B2 (en) 2020-06-23 2024-10-01 Crown Laboratories, Inc. Probiotic skin formulations
EP4308735A4 (en) * 2021-03-19 2025-02-19 Parallel Health, Inc. MICROBIOME IDENTIFICATION AND BACTERIOPHAGE FORMULATIONS
CN113066533B (zh) * 2021-04-02 2023-04-04 欧蒙医学诊断（中国）有限公司 一种mNGS病原体数据分析方法
US12502424B2 (en) 2023-05-05 2025-12-23 Sanofi Pasteur Inc. Compositions for use in treatment of acne
CN118737269B (zh) * 2024-08-30 2024-11-19 墨卓生物科技(浙江)有限公司 在单细胞微生物基因组测序结果中区分菌株的方法
US20260092332A1 (en) * 2024-10-01 2026-04-02 L'oreal Skin microbiome-based methods for acne assessment and treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033515A1 (en) * 2001-10-15 2003-04-24 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU670777B2 (en) 1992-04-16 1996-08-01 Ortho Pharmaceutical Corporation Aqueous gel vehicles for retinoids
US5836999A (en) 1995-09-28 1998-11-17 Esc Medical Systems Ltd. Method and apparatus for treating psoriasis using pulsed electromagnetic radiation
CA2251724A1 (en) 1996-04-15 1997-10-23 Paul Averback Compositions containing bacteriophages and methods of using bacteriophages to treat infections
JPH11171783A (ja) 1997-08-15 1999-06-29 Vetoquinol Sa 所定の動物に関して細胞性免疫と体重増加を生じる濃度でのバクテリアの経口投与
AU763105B2 (en) * 1998-05-22 2003-07-10 Inzinta Trading Co. Ltd Demonstrating resistance to antibiotics in microorganisms
US6726913B1 (en) 1999-10-15 2004-04-27 The Van Kampen Group, Inc. Treatment of dermal tumors, warts, and viral infections of the respiratory tract in humans using heat-killed P. acnes
JP2004520803A (ja) 2000-04-21 2004-07-15 コリクサ コーポレイション 尋常性挫瘡の治療および診断のための組成物および方法
US20030092163A1 (en) * 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
US20040157837A1 (en) 2002-11-07 2004-08-12 Serbedzija George N. Combinations for the treatment of fungal infections
NZ539076A (en) * 2005-03-29 2008-05-30 Blis Technologies Ltd Skin treatment compositions
JP5127708B2 (ja) * 2005-07-12 2013-01-23 マイクレオス べスローテン フェンノートシャップ バクテリオファージ及びその使用
US20070269813A1 (en) 2005-11-03 2007-11-22 Dewhirst Floyd E Methods and arrays for identifying human microflora
JP5201818B2 (ja) * 2006-11-10 2013-06-05 キヤノン株式会社 プローブセット、プローブ固定担体及び遺伝子検査方法
EP2184997A4 (en) 2007-07-31 2010-11-03 Univ New York DIAGNOSIS AND TREATMENT METHODS FOR THE CHARACTERIZATION OF BACTERIAL MICROORGANISMS IN SKIN DISEASES
EP2082736A1 (fr) * 2008-01-23 2009-07-29 Jean Hilaire Saurat Composition pharmaceutique à usage topique
WO2009105592A2 (en) * 2008-02-19 2009-08-27 Hogan James J Compositions and methods for detection of propionibacterium acnes nucleic acid
US9340769B2 (en) 2008-12-05 2016-05-17 The Regents Of The University Of California Methods and compositions for treating P. acnes
US9457077B2 (en) * 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
AU2011259204B2 (en) * 2010-05-27 2015-05-21 Kenichiro Hasumi Antigen peptide and use thereof
EP2825676B1 (en) * 2012-03-17 2017-12-20 The Regents of The University of California Fast diagnosis and personalized treatments for acne
EP2664919A1 (fr) * 2012-05-15 2013-11-20 Jean Hilaire Saurat Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique
JP2015524653A (ja) * 2012-07-13 2015-08-27 ロレアル 対象における薄皮状態のインビトロ診断方法及び関連用途
MX2015001751A (es) 2012-08-07 2015-11-13 Topgenix Inc Composicion topica comprendiendo bacterias transformadas que expresan un compuesto de interes.
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
JP2016509003A (ja) * 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
CN105979952B (zh) * 2013-11-25 2022-04-08 赛里斯治疗公司 协同细菌组合物以及其制造方法和用途
US9737592B1 (en) * 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
EP4299122A3 (en) 2014-05-07 2024-03-27 The Regents of The University of California Compositions and methods for treating skin and mucous membrane diseases
SI3158054T1 (sl) * 2014-06-17 2025-06-30 Crown Laboratories, Inc. Genetsko modificirane bakterije in postopki za genetsko modifikacijo bakterij
US20190008930A1 (en) * 2015-07-31 2019-01-10 The Regents Of The University Of California Mycobacterium lysterase: a novel treatment for acne
CN109562048A (zh) * 2016-02-05 2019-04-02 加州大学评议会 用于促进皮肤健康的组合物和方法
US9889165B2 (en) * 2016-04-21 2018-02-13 Naked Biome, Inc. Compositions and methods for treatment of skin disorders
CN109689861A (zh) * 2016-05-15 2019-04-26 加州大学评议会 用于治疗痤疮的组合物和方法
US11541081B2 (en) * 2016-10-19 2023-01-03 S-Biomedic Nv Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains
US20210177920A1 (en) * 2017-12-05 2021-06-17 Biomx Ltd. Bacteriophage treatment for acne and biofilms
US12102710B2 (en) * 2020-06-23 2024-10-01 Crown Laboratories, Inc. Probiotic skin formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033515A1 (en) * 2001-10-15 2003-04-24 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GENBANK PROPIONIBACTERIUM ACNES KPA171202, COMPLETE GENOME, vol. ACCESSION No.AE017283, 21-NOV-2011, JPN6017047020, pages 2017 - 11, ISSN: 0003876036 *
J INVEST DERMATOL. EPUB 2013 JAN 21, VOL.133, NO.9, P.2152-2160, JPN6017000570, ISSN: 0003876035 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017029133A (ja) * 2015-07-21 2017-02-09 ＴＡＫ−Ｃｉｒｃｕｌａｔｏｒ株式会社 身体状態の評価方法、情報の提示方法、および身体状態を改善又は予防する物質のスクリーニング方法
JP2017029174A (ja) * 2015-07-21 2017-02-09 ＴＡＫ−Ｃｉｒｃｕｌａｔｏｒ株式会社 身体状態の評価方法、情報の提示方法、および身体状態を改善又は予防する物質のスクリーニング方法
US11802310B2 (en) 2015-07-21 2023-10-31 Myskin Corporation Method for evaluating physical conditions, method for presenting information, and method for screening for substance capable of improving or preventing physical conditions
WO2017014256A1 (ja) * 2015-07-21 2017-01-26 ＴＡＫ－Ｃｉｒｃｕｌａｔｏｒ株式会社 身体状態の評価方法、情報の提示方法、および身体状態を改善又は予防する物質のスクリーニング方法
JP2017086072A (ja) * 2015-11-04 2017-05-25 学校法人慶應義塾 対象物の使用者を判定する方法
JP2019509263A (ja) * 2016-02-05 2019-04-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 皮膚の健康増進用組成物及び健康増進方法
US11207357B2 (en) 2016-04-21 2021-12-28 Symbiome, Inc. Compositions and methods for treatment of skin disorders
US9889165B2 (en) 2016-04-21 2018-02-13 Naked Biome, Inc. Compositions and methods for treatment of skin disorders
US10293007B2 (en) 2016-04-21 2019-05-21 Naked Biome, Inc. Compositions and methods for treatment of skin disorders
JP2018000206A (ja) * 2016-07-08 2018-01-11 花王株式会社 核酸試料の調製方法
WO2018008319A1 (ja) * 2016-07-08 2018-01-11 花王株式会社 核酸試料の調製方法
JP6231252B1 (ja) * 2016-07-08 2017-11-15 花王株式会社 核酸試料の調製方法
US11913061B2 (en) 2016-07-08 2024-02-27 Kao Corporation Method for preparing nucleic acid sample
WO2018084112A1 (ja) 2016-11-01 2018-05-11 株式会社桃谷順天館 アクネ菌株選択的抗菌剤
JP2020517735A (ja) * 2017-04-21 2020-06-18 ピー・エイチ・アイ・セラピューティクス・インコーポレイテッド ざ瘡を治療するためのプロピオニバクテリウムアクネス（Ｐｒｏｐｉｏｎｉｂａｃｔｅｒｉｕｍ ａｃｎｅｓ）バクテリオファージを含む組成物
JP2024099592A (ja) * 2017-04-21 2024-07-25 ピー・エイチ・アイ・セラピューティクス・インコーポレイテッド ざ瘡を治療するためのプロピオニバクテリウムアクネス（Ｐｒｏｐｉｏｎｉｂａｃｔｅｒｉｕｍ ａｃｎｅｓ）バクテリオファージを含む組成物
JP7595459B2 (ja) 2017-04-21 2024-12-06 ピー・エイチ・アイ・セラピューティクス・インコーポレイテッド ざ瘡を治療するためのプロピオニバクテリウムアクネス（Ｐｒｏｐｉｏｎｉｂａｃｔｅｒｉｕｍ ａｃｎｅｓ）バクテリオファージを含む組成物
JP7801389B2 (ja) 2017-04-21 2026-01-16 ピー・エイチ・アイ・セラピューティクス・インコーポレイテッド ざ瘡を治療するためのプロピオニバクテリウムアクネス（Ｐｒｏｐｉｏｎｉｂａｃｔｅｒｉｕｍ ａｃｎｅｓ）バクテリオファージを含む組成物
JP2022539826A (ja) * 2019-07-12 2022-09-13 ビオメリュー 細菌発生の疫学的識別および監視のための方法
JP7644082B2 (ja) 2019-07-12 2025-03-11 ビオメリュー 細菌発生の疫学的識別および監視のための方法

Also Published As

Publication number Publication date
JP2021013395A (ja) 2021-02-12
US20150086581A1 (en) 2015-03-26
CN110055320A (zh) 2019-07-26
WO2013142378A1 (en) 2013-09-26
US20240117446A1 (en) 2024-04-11
AU2013235340A1 (en) 2014-10-16
AU2019219817A1 (en) 2019-09-12
CN104364394B (zh) 2019-02-22
AU2020227049A1 (en) 2020-09-17
EP2825676A4 (en) 2015-09-30
US20210123092A1 (en) 2021-04-29
EP3692999A1 (en) 2020-08-12
US20170058328A1 (en) 2017-03-02
SG11201405783VA (en) 2014-10-30
US20190316183A1 (en) 2019-10-17
CA2867621A1 (en) 2013-09-26
JP2019050833A (ja) 2019-04-04
EP3360560A1 (en) 2018-08-15
AU2013235340B2 (en) 2019-05-23
EP2825676A1 (en) 2015-01-21
WO2013142378A9 (en) 2014-01-23
US11692229B2 (en) 2023-07-04
EP2825676B1 (en) 2017-12-20
HK1207402A1 (en) 2016-01-29
US10364473B2 (en) 2019-07-30
BR112014023005A2 (pt) 2017-07-18
CN104364394A (zh) 2015-02-18

Similar Documents

Publication Publication Date Title
US11692229B2 (en) Fast diagnosis and personalized treatments for acne
Springman et al. Pilus distribution among lineages of group b streptococcus: an evolutionary and clinical perspective
Fittipaldi et al. Full-genome dissection of an epidemic of severe invasive disease caused by a hypervirulent, recently emerged clone of group A Streptococcus
Novais et al. Co-diversification of Enterococcus faecium core genomes and PBP5: evidences of pbp5 horizontal transfer
Schindler et al. Group B streptococcus virulence factors associated with different clinical syndromes: Asymptomatic carriage in pregnant women and early-onset disease in the newborn
Wu et al. Competitive dominance within biofilm consortia regulates the relative distribution of pneumococcal nasopharyngeal density
Ntozini et al. Molecular epidemiology of invasive group B Streptococcus in South Africa, 2019–2020
Zhang et al. Molecular signatures identify a candidate target of balancing selection in an arcD-like gene of Staphylococcus epidermidis
HK40011589A (en) Fast diagnosis and personalized treatments for acne
Speck et al. Characterization of Streptococcus equi subsp. ruminatorum isolated from spotted hyenas (Crocuta crocuta) and plains zebras (Equus burchelli), and identification of a M-like protein (SrM) encoding gene
HK1207402B (zh) 痤疮的快速诊断和个体化治疗
Kitano et al. First human case of infected lymphocele with bloodstream infection caused by Staphylococcus coagulans transmitted from a pet dog: a case report
Khan Detailed genomic and antimicrobial resistance comparison of UK Streptococcus agalactiae isolates from adults to those of diverse global origins
Piña-Iturbe et al. Subinhibitory antibiotic concentrations promote the excision of a genomic island carried by the globally spread carbapenem-resistant Klebsiella pneumoniae sequence type 258
Conde-Pérez et al. Evidence for translocation of oral Parvimonas micra from the subgingival sulcus of the human oral cavity to the colorectal adenocarcinoma
Zhendong et al. Isolation and identification of two highly virulent Glaesserella parasuis serovar 7 strains in China
Ene Exploring the Role of Lactobacillus jensenii and Lactobacillus mulieris in the Urogenital Tract
Abdullah Nurul Diana Dzaraly1, Mohd Nasir Mohd Desa1Ε, AbdulRahman Muthanna1, Siti Norbaya Masri2, Niazlin Mohd Taib2, Zarizal Suhaili1, 3, Nurshahira Sulaiman1, Nurul Hana Zainal Baharin1, Cheah Yun Shuan1, Zarina Ariffin1, Nor Iza A. Rahman4, Farahiyah Mohd Rani4, Navindra Kumari Palanisamy5, Tuan Suhaila Tuan Soh6 &
Graham Antibacterial activities of Propionibacterium acnes bacteriophages against a diverse collection of P. acnes clinical isolates: prospects for novel alternative therapies for acne vulgaris
Willner Viral metagenomics in host-associated systems
Novais et al. Peixe Land Coque TM (2016) Co-diversification of Enterococcus faecium Core Genomes and PBP5: Evidences of pbp5 Horizontal Transfer
Proud Examining the Role of Transformation in the Acquisition of Resistance and Rescue of Genomes from Oxidative Stress
Gaiarsa EVOLUTION, COMPARATIVE GENOMICS AND GENOMIC EPIDEMIOLOGY OF BACTERIA OF PUBLIC HEALTH IMPORTANCE
Nagy ESGARAB
McAdam Population analysis of bacterial pathogens on distinct temporal and spatial scales

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190110

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190121

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190222